Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.
Bertrand Y. Tuan, MD
Advertisement
Articles by Bertrand Y. Tuan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5